Promoters and control elements: designing expression cassettes for gene therapy.
暂无分享,去创建一个
S J White | S. J. White | S. Nicklin | E. Papadakis | A. Baker | E D Papadakis | S A Nicklin | A H Baker | A. Baker | Andrew H. Baker
[1] S. Barsky,et al. Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector. , 1998, Anticancer research.
[2] T. Hawley,et al. Lentiviral vectors for enhanced gene expression in human hematopoietic cells. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] G M Tozer,et al. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. , 2000, European journal of cancer.
[4] T. Flotte,et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[5] S. Rivella,et al. Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. , 1998, Seminars in hematology.
[6] Karen Moore,et al. Codon optimization, genetic insulation, and an rtTA reporter improve performance of the tetracycline switch , 1999, Transgenic Research.
[7] J H Hendry,et al. Development of synthetic promoters for radiation-mediated gene therapy , 2000, Gene Therapy.
[8] L. Taichman,et al. Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy , 1997, Journal of virology.
[9] A. Udvardy. Dividing the empire: boundary chromatin elements delimit the territory of enhancers , 1999, The EMBO journal.
[10] D. Collen,et al. Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I. , 2002, Human gene therapy.
[11] M. Gossen,et al. Transcriptional activation by tetracyclines in mammalian cells. , 1995, Science.
[12] R. Ritter,et al. Development of a Langerhans cell-targeted gene therapy format using a dendritic cell-specific promoter , 2001, Gene Therapy.
[13] Thulé Pm,et al. Regulated hepatic insulin gene therapy of STZ-diabetic rats. , 2000 .
[14] R. Kingston,et al. ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. , 1999, Genes & development.
[15] T. Ratliff. Robust prostate-specific expression for the targeted gene therapy based on the human kallikrein 2 promoter. , 2002, The Journal of urology.
[16] B. Luckow,et al. Identification of new regulatory sequences far upstream of the mouse monocyte chemoattractant protein-1 gene. , 2001, Genomics.
[17] A. Nienhuis,et al. High-level erythroid lineage-directed gene expression using globin gene regulatory elements after lentiviral vector-mediated gene transfer into primitive human and murine hematopoietic cells. , 2002, Human gene therapy.
[18] J. T. Kadonaga,et al. Enhancer-promoter specificity mediated by DPE or TATA core promoter motifs. , 2001, Genes & development.
[19] A. Beaudet,et al. Long-Term Stable Correction of Low-Density Lipoprotein Receptor–Deficient Mice With a Helper-Dependent Adenoviral Vector Expressing the Very Low-Density Lipoprotein Receptor , 2001, Circulation.
[20] C. Jorgensen,et al. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. , 2002, Human gene therapy.
[21] S. Kochanek,et al. High-capacity adenoviral vectors for gene transfer and somatic gene therapy. , 1999, Human gene therapy.
[22] E. Marbán,et al. Adenovirus-mediated inducible gene expression in vivo by a hybrid ecdysone receptor. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] S. Kung,et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. , 1998, Blood.
[24] K. Kurachi,et al. Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver. , 1996, Viral immunology.
[25] D. Curiel,et al. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. , 2002, Human gene therapy.
[26] D. Curiel,et al. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors , 1999, Cancer Gene Therapy.
[27] J. Ellis,et al. Silencing of gene expression: implications for design of retrovirus vectors , 2001, Reviews in medical virology.
[28] Jianzhu Chen,et al. A Nuclear Matrix Attachment Region Upstream of the T Cell Receptor β Gene Enhancer Binds Cux/CDP and SATB1 and Modulates Enhancer-dependent Reporter Gene Expression but Not Endogenous Gene Expression* , 1998, The Journal of Biological Chemistry.
[29] C. Ring. Cytolytic viruses as potential anti-cancer agents. , 2002, The Journal of general virology.
[30] J. Workman,et al. The many HATs of transcription coactivators. , 2000, Trends in biochemical sciences.
[31] O. Isacson,et al. A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. , 2001, Human gene therapy.
[32] S. Rivella,et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. , 2000, Nature.
[33] T. Burke,et al. Drosophila TFIID binds to a conserved downstream basal promoter element that is present in many TATA-box-deficient promoters. , 1996, Genes & development.
[34] N. Déglon,et al. Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] D. Kohn,et al. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[36] R. Schwartz,et al. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences , 1999, Nature Biotechnology.
[37] Jeffrey A. Lefstin,et al. Allosteric effects of DNA on transcriptional regulators , 1998, Nature.
[38] M. Imperiale,et al. Promoter Attenuation in Gene Therapy: Interferon-γ and Tumor Necrosis Factor-α Inhibit Transgene Expression , 1997 .
[39] A. Baiker,et al. A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. , 1999, Nucleic acids research.
[40] Robert O J Weinzierl. Mechanisms of Gene Expression: Structure, Function and Evolution of the Basal Transcriptional Machinery , 1999 .
[41] A. Beaudet,et al. Helper-dependent adenoviral vectors. , 2002, Methods in enzymology.
[42] J. Uney,et al. Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[43] R. Aikawa,et al. Cardiomyocyte-specific Gene Expression Following Recombinant Adeno-associated Viral Vector Transduction* , 2002, The Journal of Biological Chemistry.
[44] T. Hope,et al. Woodchuck Hepatitis Virus Contains a Tripartite Posttranscriptional Regulatory Element , 1998, Journal of Virology.
[45] M. Bednarski,et al. Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.
[46] J. Wilson,et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[47] HL Davis,et al. Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters , 2001, Gene Therapy.
[48] A. Beaudet,et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity , 1998, Nature Genetics.
[49] M. Braddock,et al. Delivery and expression of fluid shear stress-inducible promoters to the vessel wall: applications for cardiovascular gene therapy. , 1999, Human gene therapy.
[50] R. Roeder,et al. Core promoter-specific function of a mutant transcription factor TFIID defective in TATA-box binding. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[51] T. Yamano,et al. Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[52] C. Bonifer,et al. Developmental regulation of eukaryotic gene loci: which cis-regulatory information is required? , 2000, Trends in genetics : TIG.
[53] P. Bosma,et al. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma , 2001, Cancer Gene Therapy.
[54] Atique U. Ahmed,et al. Cancer gene therapy: Part 1. Vector development and regulation of gene expression. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).
[55] C. Barbas,et al. Positive and negative regulation of endogenous genes by designed transcription factors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[56] G. Cutting,et al. Optimized regulation of gene expression using artificial transcription factors. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[57] D. Nettelbeck,et al. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. , 2002, Cancer research.
[58] T. He,et al. Tetracycline-regulated Gene Expression Mediated by a Novel Chimeric Repressor That Recruits Histone Deacetylases in Mammalian Cells* , 2001, The Journal of Biological Chemistry.
[59] C. Férec,et al. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. , 2001, Human gene therapy.
[60] D. Deen,et al. Use of hypoxia-regulated gene expression in tumor-specific gene therapy. , 2001, Current opinion in investigational drugs.
[61] P. Becker,et al. Histone acetylation: a switch between repressive and permissive chromatin , 2002, EMBO reports.
[62] T. Libermann,et al. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. , 1999, Human gene therapy.
[63] J. Gu,et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. , 2000, Cancer research.
[64] Guy Riddihough. The Other RNA World , 2002, Science.
[65] T. Okanoue,et al. High expression of transgenes mediated by hybrid retroviral vectors in hepatocytes: comparison of promoters from murine retroviruses in vitro and in vivo , 2002, Gene Therapy.
[66] Hyun Chul Lee,et al. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue , 2000, Nature.
[67] M. Weitzman,et al. Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. , 1999, Human gene therapy.
[68] A. Lieber,et al. Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo , 2000, Gene Therapy.
[69] P B Sigler,et al. The structural basis for the oriented assembly of a TBP/TFB/promoter complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[70] H. Sweeney,et al. Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[71] H. Sweeney,et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. , 2001, Human gene therapy.
[72] G. Orphanides,et al. A Unified Theory of Gene Expression , 2002, Cell.
[73] D. Elleder,et al. CpG island protects Rous sarcoma virus-derived vectors integrated into nonpermissive cells from DNA methylation and transcriptional suppression. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[74] P. Levings,et al. The human b-globin locus control region A center of attraction , 2002 .
[75] C C Case,et al. Synthetic Zinc Finger Transcription Factor Action at an Endogenous Chromosomal Site , 2000, The Journal of Biological Chemistry.
[76] J. Bromberg,et al. TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[77] T. Kohwi-Shigematsu,et al. An Atypical Homeodomain in SATB1 Promotes Specific Recognition of the Key Structural Element in a Matrix Attachment Region* , 1997, The Journal of Biological Chemistry.
[78] S. Ribault,et al. Chimeric Smooth Muscle-Specific Enhancer/Promoters: Valuable Tools for Adenovirus-Mediated Cardiovascular Gene Therapy , 2001, Circulation research.
[79] D. Trono,et al. Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.
[80] S. Madoiwa,et al. Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoter , 2001, Gene Therapy.
[81] D. Nettelbeck,et al. A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control , 1999, Gene Therapy.
[82] Sanjiv S Gambhir,et al. Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[83] F. Graham,et al. Effects of Stuffer DNA on Transgene Expression from Helper-Dependent Adenovirus Vectors , 1999, Journal of Virology.
[84] Kirby D. Johnson,et al. Distinct mechanisms control RNA polymerase II recruitment to a tissue-specific locus control region and a downstream promoter. , 2001, Molecular cell.
[85] J. Escobedo,et al. Tightly regulated long-term erythropoietin expression in vivo using tet-inducible recombinant adeno-associated viral vectors. , 2002, Human gene therapy.
[86] D. Collen,et al. Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. , 2000, Human gene therapy.
[87] D. Curiel,et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo , 2001, Nature Biotechnology.
[88] G M Edelman,et al. Synthetic promoter elements obtained by nucleotide sequence variation and selection for activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[89] T. Mayumi,et al. Optimization of transcriptional regulatory elements for constructing plasmid vectors. , 2001, Gene.
[90] B. Foley,et al. Modification of multiple transcriptional regulatory elements in a Moloney murine leukemia virus gene transfer vector circumvents silencing in fibroblast grafts and increases levels of expression of the transferred enzyme , 2002, Gene Therapy.
[91] D. Nettelbeck,et al. Gene therapy: designer promoters for tumour targeting. , 2000, Trends in genetics : TIG.
[92] R. Roeder,et al. The role of general initiation factors in transcription by RNA polymerase II. , 1996, Trends in biochemical sciences.
[93] M. Dragunow,et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes , 2001, Gene Therapy.
[94] H. Mizuguchi,et al. The tet‐off system is more effective than the tet‐on system for regulating transgene expression in a single adenovirus vector , 2002, The journal of gene medicine.
[95] N. Lemoine,et al. Insulation of a conditionally expressed transgene in an adenoviral vector , 1999, Gene Therapy.
[96] Y. Li,et al. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. , 2002, Cancer research.
[97] S. Liebhaber,et al. The human growth hormone locus control region mediates long-distance transcriptional activation independent of nuclear matrix attachment regions. , 2001, Nucleic acids research.
[98] A. Pavirani,et al. Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. , 1996, Gene therapy.
[99] K. Nomura,et al. Analysis of sequence‐dependent curvature in matrix attachment regions , 2001, FEBS letters.
[100] Y. Tsao,et al. Disease-Inducible Transgene Expression from a Recombinant Adeno-Associated Virus Vector in a Rat Arthritis Model , 1999, Journal of Virology.
[101] H. Lochmüller,et al. Interferons impair early transgene expression by adenovirus-mediated gene transfer in muscle cells , 1998, Journal of Molecular Medicine.
[102] Y. Chiang,et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. , 1999, Human gene therapy.
[103] R. Alemany,et al. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[104] S. Raguz,et al. Muscle-specific locus control region activity associated with the human desmin gene. , 1998, Developmental biology.
[105] J. Chamberlain,et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[106] R. Crystal,et al. Intermittent, repetitive corticosteroid-induced upregulation of platelet levels after adenovirus-mediated transfer to the liver of a chimeric glucocorticoid-responsive promoter controlling the thrombopoietin cDNA. , 1998, Blood.
[107] S. Kumar,et al. Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters , 2001, Gene Therapy.
[108] P. Laipis,et al. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors , 2001, Gene Therapy.
[109] C. Allis,et al. The language of covalent histone modifications , 2000, Nature.
[110] S. Kochanek,et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[111] T. Burke,et al. The downstream core promoter element, DPE, is conserved from Drosophila to humans and is recognized by TAFII60 of Drosophila. , 1997, Genes & development.
[112] H. Ertl,et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1996, Gene therapy.
[113] T. VandenDriessche,et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[114] G. Demers,et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy , 2001, Nature Biotechnology.
[115] N. Rainov,et al. Hypoxia-inducible transgene expression in differentiated human NT2N neurons – a cell culture model for gene therapy of postischemic neuronal loss , 2001, Gene Therapy.
[116] A. Belldegrun,et al. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors , 2001, Gene Therapy.
[117] J. T. Kadonaga,et al. The “Dark Side” of Chromatin Remodeling Repressive Effects on Transcription , 1999, Cell.
[118] H. Mizuguchi,et al. Characteristics of adenovirus-mediated tetracycline-controllable expression system. , 2001, Biochimica et biophysica acta.
[119] S. Cheng,et al. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[120] Michael R. Green,et al. Promoter targeting by adenovirus E1a through interaction with different cellular DNA-binding domains , 1994, Nature.
[121] S. Bidlingmaier,et al. Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A. , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[122] A. Mahfoudi,et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. , 2002, Human gene therapy.
[123] K. Loeb,et al. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[124] F. Gage,et al. High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[125] A. Kingsman,et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer , 1999, Gene Therapy.
[126] Michel Sadelain,et al. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin , 2000, Nature.
[127] D. Pardoll,et al. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. , 2002, Blood.
[128] M. Lusky,et al. In Vitro and In Vivo Biology of Recombinant Adenovirus Vectors with E1, E1/E2A, or E1/E4 Deleted , 1998, Journal of Virology.
[129] R. Crystal,et al. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells , 1999, Cancer Gene Therapy.
[130] B. Trapnell,et al. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. , 1998, Human gene therapy.
[131] C. Allis,et al. Translating the Histone Code , 2001, Science.
[132] G. Stamatoyannopoulos,et al. Evidence that DNase I hypersensitive site 5 of the human beta-globin locus control region functions as a chromosomal insulator in transgenic mice. , 2002, Nucleic Acids Research.
[133] N. Yang,et al. Cytokine transgene expression and promoter usage in primary CD34+ cells using particle-mediated gene delivery. , 1998, Human gene therapy.
[134] R. Tjian,et al. Orchestrated response: a symphony of transcription factors for gene control. , 2000, Genes & development.
[135] De-Pei Liu,et al. Insulator: from chromatin domain boundary to gene regulation , 2001, Human Genetics.
[136] S. Berger. An embarrassment of niches: the many covalent modifications of histones in transcriptional regulation , 2001, Oncogene.
[137] M. Kay,et al. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. , 2002, Blood.
[138] J. Bode,et al. Biological significance of unwinding capability of nuclear matrix-associating DNAs. , 1992, Science.
[139] K. Eguchi,et al. Utilization of variant-type of human α-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma , 1999, Gene Therapy.
[140] J. Mcarthur,et al. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. , 2001, Blood.
[141] R. Scheule,et al. CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[142] M. W. Flye,et al. Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alpha 1-antitrypsin in vivo. , 1996, Human gene therapy.
[143] R. Tjian,et al. Promoter-selective properties of the TBP-related factor TRF1. , 2000, Science.
[144] D. Kayda,et al. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[145] Magnus Molin,et al. Two Novel Adenovirus Vector Systems Permitting Regulated Protein Expression in Gene Transfer Experiments , 1998, Journal of Virology.
[146] B. Byrne,et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. , 2001, Human gene therapy.
[147] Erwin G. Van Meir,et al. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells , 2001, Gene Therapy.
[148] Steven A Curley,et al. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. , 2002, Cancer research.
[149] K. Brand,et al. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach , 1998, Gene Therapy.
[150] H. Chen,et al. Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus , 1998, Gene Therapy.
[151] R. Estrada. De los ángeles , 1987 .
[152] F. Moreau-Gaudry,et al. High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. , 2001, Blood.
[153] R. Evans,et al. Identification of ligands and coligands for the ecdysone-regulated gene switch. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[154] J. Yee,et al. Locus Control Region of the Human CD2Gene in a Lentivirus Vector Confers Position-Independent Transgene Expression , 2001, Journal of Virology.
[155] C. Walsh,et al. Cytosine methylation and the ecology of intragenomic parasites. , 1997, Trends in genetics : TIG.
[156] C. Caskey,et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[157] J. Wilson,et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[158] A. Harris,et al. Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery. , 1997, Human gene therapy.
[159] M. Savontaus,et al. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells , 2002, Gene Therapy.
[160] T. Townes,et al. Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[161] P. Thulé,et al. Regulated hepatic insulin gene therapy of STZ-diabetic rats , 2000, Gene Therapy.
[162] G. Stamatoyannopoulos,et al. Development of a Condensed Locus Control Region Cassette and Testing in Retrovirus Vectors forAγ-Globin , 1998 .
[163] Mark Groudine,et al. A Functional Enhancer Suppresses Silencing of a Transgene and Prevents Its Localization Close to Centromeric Heterochromatin , 1999, Cell.
[164] C. Chiang,et al. The Intronless and TATA-less HumanTAF II 55 Gene Contains a Functional Initiator and a Downstream Promoter Element* , 2001, The Journal of Biological Chemistry.
[165] V. Rivera,et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. , 1999, Science.
[166] A. Dominiczak,et al. Analysis of Cell-Specific Promoters for Viral Gene Therapy Targeted at the Vascular Endothelium , 2001, Hypertension.
[167] D. Curiel,et al. Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[168] Regulable Expression of Inhibin A in Wild-Type and Inhibinα Null Mice , 2000 .
[169] M. Meseck,et al. Auto-regulated hepatic insulin gene expression in type 1 diabetic rats. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[170] S. Cannistra,et al. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. , 1999, Cancer research.
[171] M. Kay,et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors , 1997, Journal of virology.
[172] C. Ged,et al. Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[173] L. Ailles,et al. Transcriptional Targeting of Lentiviral Vectors by Long Terminal Repeat Enhancer Replacement , 2002, Journal of Virology.
[174] A. Krieg. Direct Immunologic activities of CpG DNA and implications for gene therapy , 1999, The journal of gene medicine.
[175] J. Gu,et al. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[176] E. Krausz,et al. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53 , 2001, Gene Therapy.
[177] A. Clark,et al. Chromosomal sequences flanking an efficiently expressed transgene dramatically enhance its expression. , 2001, Gene.
[178] C. Higgins,et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor1α promoter , 2001, Gene Therapy.
[179] A. Tanswell,et al. Development of an epithelium-specific expression cassette with human DNA regulatory elements for transgene expression in lung airways. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[180] R. Beerli,et al. Engineering polydactyl zinc-finger transcription factors , 2002, Nature Biotechnology.
[181] M. Sadelain,et al. Glucose 6-phosphate dehydrogenase expression is less prone to variegation when driven by its own promoter. , 2001, Gene.
[182] Inder M. Verma,et al. Gene therapy: trials and tribulations , 2000, Nature Reviews Genetics.
[183] S. Kyo,et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. , 2000, Human gene therapy.
[184] P. Jones,et al. The DNA methylation paradox. , 1999, Trends in genetics : TIG.
[185] M. Green,et al. TBP-associated factors (TAFIIs): multiple, selective transcriptional mediators in common complexes. , 2000, Trends in biochemical sciences.
[186] A Afek,et al. Tissue-specific gene therapy directed to tumor angiogenesis , 2001, Gene Therapy.
[187] V. Rivera,et al. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[188] D J Segal,et al. Development of Zinc Finger Domains for Recognition of the 5′-ANN-3′ Family of DNA Sequences and Their Use in the Construction of Artificial Transcription Factors* , 2001, The Journal of Biological Chemistry.
[189] M. Tagawa,et al. A promoter region of midkine gene can activate transcription of an exogenous suicide gene in human pancreatic cancer. , 2002, Anticancer Research.
[190] Y. Wang,et al. Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator , 1997, Gene Therapy.
[191] J. Mulé,et al. Immune evasion by muscle-specific gene expression in dystrophic muscle. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[192] J. Nalbantoglu,et al. The short MCK1350 promoter/enhancer allows for sufficient dystrophin expression in skeletal muscles of mdx mice. , 2002, Biochemical and biophysical research communications.
[193] A. Fattaey,et al. An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.
[194] S. Smale,et al. Core promoters: active contributors to combinatorial gene regulation. , 2001, Genes & development.
[195] D. Kioussis,et al. Locus control regions and epigenetic chromatin modifiers. , 2000, Current opinion in genetics & development.
[196] M. Imperiale,et al. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. , 1997, Human gene therapy.
[197] S. Raguz,et al. LCR-mediated, long-term tissue-specific gene expression within replicating episomal plasmid and cosmid vectors , 2002, Gene Therapy.
[198] G. Splitter,et al. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. , 1995, Human gene therapy.
[199] A. Schambach,et al. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[200] D. Nettelbeck,et al. The flt-1 promoter for transcriptional targeting of teratocarcinoma. , 2002, Cancer research.
[201] M. Kay,et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[202] A. Hartmann,et al. SAF-B protein couples transcription and pre-mRNA splicing to SAR/MAR elements. , 1998, Nucleic acids research.
[203] S. Liebhaber,et al. A defined locus control region determinant links chromatin domain acetylation with long-range gene activation. , 2002, Molecular cell.
[204] S. Bidlingmaier,et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[205] F. McCormick,et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. , 2002, Cancer cell.
[206] D. Antelman,et al. Tissue-specific expression of an anti-proliferative hybrid transgene from the human smooth muscle α-actin promoter suppresses smooth muscle cell proliferation and neointima formation , 2001, Gene Therapy.
[207] T. Pierson,et al. Regulable expression of inhibin A in wild-type and inhibin alpha null mice. , 2000, Molecular endocrinology.
[208] G. Vrbóva,et al. Myosin regulatory elements as vectors for gene transfer by intramuscular injection , 1998, Gene Therapy.
[209] O. Nyanguile,et al. A versatile framework for the design of ligand-dependent, transgene-specific transcription factors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[210] T. Honda,et al. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells , 2001, Gene Therapy.
[211] M. W. Flye,et al. Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[212] H. Katus,et al. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. , 1997, Cardiovascular research.
[213] R. Cortese,et al. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. , 2000, Human gene therapy.
[214] A. Patterson,et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation , 2002, Gene Therapy.
[215] S. Gasser,et al. Positions of Potential:Nuclear Organization and Gene Expression , 2001, Cell.
[216] N. Sarvetnick,et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[217] L. Wang,et al. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. , 1996, Gene therapy.
[218] H. Alexander,et al. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. , 1999, Human gene therapy.
[219] S. Rivella,et al. The cHS4 Insulator Increases the Probability of Retroviral Expression at Random Chromosomal Integration Sites , 2000, Journal of Virology.
[220] In-Hoo Kim,et al. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[221] D. Bodine,et al. Development of a Stable Retrovirus Vector Capable of Long‐Term Expression of γ‐Globin mRNA in Mouse Erythrocytes , 2001, Annals of the New York Academy of Sciences.
[222] F. Deist,et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.
[223] J. Jessup,et al. Replicating adenoviral vector–mediated transfer of a heat-inducible double suicide gene for gene therapy , 2001, Cancer Gene Therapy.
[224] D. Klatzmann,et al. Transcriptional Targeting to Anterior Pituitary Lactotrophic Cells Using Recombinant Adenovirus Vectors in Vitro and in Vivo in Normal and Estrogen/Sulpiride-Induced Hyperplasic Anterior Pituitaries. , 2000, Endocrinology.
[225] P. Lowenstein,et al. Cell-type-specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[226] R. Herzog,et al. skeletal actin/CMV hybrid enhancer/promoter Improved muscle-derived expression of human coagulation factor IX from a , 2013 .
[227] A. Wolffe,et al. Review: chromatin structural features and targets that regulate transcription. , 2000, Journal of structural biology.
[228] T. Akhurst,et al. Tumor-specific transcriptional targeting of suicide gene therapy , 2002, Gene Therapy.
[229] A. Tanswell,et al. Targeting transgene expression for cystic fibrosis gene therapy. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[230] C. Verrijzer,et al. DNA binding site selection by RNA polymerase II TAFs: a TAFII250–TAFII150 complex recognizes the Initiator , 1999, The EMBO journal.
[231] H. Bujard,et al. Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[232] B. Baum,et al. Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands. , 1996, Human gene therapy.
[233] D. Kohn,et al. Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. , 1999, Blood.
[234] R. Cortese,et al. Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators. , 2002, Human gene therapy.
[235] P. Opolon,et al. Heart-specific targeting of beta-galactosidase by the ventricle-specific cardiac myosin light chain 2 promoter using adenovirus vectors. , 1998, Human gene therapy.
[236] S. Weitzman,et al. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach , 2000, Cancer Gene Therapy.
[237] T. Krontiris,et al. The thymocyte-specific MAR binding protein, SATB1, interacts in vitro with a novel variant of DNA-directed RNA polymerase II, subunit 11. , 2002, Genomics.
[238] S. Kochanek,et al. Variables Affecting In Vivo Performance of High-Capacity Adenovirus Vectors , 2002, Journal of Virology.
[239] C. L. Johnson,et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. , 2000, Human gene therapy.
[240] J. Dong,et al. Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters , 2001, Gene Therapy.
[241] R. Dikstein,et al. TAFII105 mediates activation of anti‐apoptotic genes by NF‐κB , 1998 .
[242] M. T. Hasan,et al. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[243] K. Webster,et al. Regulated expression of a foreign gene targeted to the ischaemic myocardium. , 1997, Cardiovascular research.
[244] R. Crystal,et al. Exogenous control of cardiac gene therapy: evidence of regulated myocardial transgene expression after adenovirus and adeno-associated virus transfer of expression cassettes containing corticosteroid response element promoters. , 1999, The Journal of thoracic and cardiovascular surgery.
[245] R. Tjian,et al. TATA box-binding protein (TBP)-related factor 2 (TRF2), a third member of the TBP family. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[246] A Klug,et al. Improved DNA binding specificity from polyzinc finger peptides by using strings of two-finger units. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[247] R. Evans,et al. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[248] M. Kay,et al. Modified HIV-1 based lentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[249] R. Kingston,et al. Cooperation between Complexes that Regulate Chromatin Structure and Transcription , 2002, Cell.
[250] J. Bromberg,et al. TNFα and IFNγ Induced by Innate Anti-adenoviral Immune Responses Inhibit Adenovirus-Mediated Transgene Expression , 2001 .
[251] L. Naldini,et al. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. , 2002, Human gene therapy.
[252] S. Zolotukhin,et al. Hypothalamic delivery of doxycycline-inducible leptin gene allows for reversible transgene expression and physiological responses , 2002, Gene Therapy.
[253] Katherine A. High,et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.
[254] S. Karlsson,et al. Adenoviral vector design for high-level transgene expression in primitive human hematopoietic progenitors , 2000, Gene Therapy.
[255] A. Beaudet,et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. , 1999, Human gene therapy.
[256] T. Mayumi,et al. Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[257] W. C. Forrester,et al. Evidence for a locus activation region: the formation of developmentally stable hypersensitive sites in globin-expressing hybrids. , 1987, Nucleic acids research.
[258] M. Carey,et al. The Enhanceosome and Transcriptional Synergy , 1998, Cell.
[259] S. Liebhaber,et al. Targeted Recruitment of Histone Acetyltransferase Activity to a Locus Control Region* , 2000, The Journal of Biological Chemistry.
[260] K. Schmidt-Ott,et al. Vigilant Vector: Heart-Specific Promoter in an Adeno-Associated Virus Vector for Cardioprotection , 2002, Hypertension.
[261] M. During,et al. Insulators coupled to a minimal bidirectional tet cassette for tight regulation of rAAV-mediated gene transfer in the mammalian brain , 2001, Gene Therapy.
[262] J. Lebkowski,et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters , 2001, Gene Therapy.
[263] H. Blau,et al. Tet B or not tet B: advances in tetracycline-inducible gene expression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[264] M. Roth,et al. Transcription units as RNA processing units. , 1997, Genes & development.
[265] M. Gossen,et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[266] D. Bodine,et al. Long-term expression of gamma-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma-globin gene fused to the ankyrin-1 promoter. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[267] J. Manley,et al. RNA polymerase II and the integration of nuclear events. , 2000, Genes & development.
[268] H. Blau,et al. Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16 , 1998, Nature Genetics.
[269] James M. Wilson,et al. Regulated Gene Expression in Gene Therapy , 2001, Annals of the New York Academy of Sciences.
[270] M. Keogh,et al. Design of a muscle cell-specific expression vector utilising human vascular smooth muscle α-actin regulatory elements , 1999, Gene Therapy.
[271] J. Simons,et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. , 1997, Cancer research.
[272] S. Elgin,et al. Putting Boundaries on Silence , 1999, Cell.
[273] A. Wolffe,et al. Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. , 1999, Journal of molecular endocrinology.
[274] S. Smale,et al. Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. , 1997, Biochimica et biophysica acta.
[275] B. O’Malley,et al. Adenovirus-mediated regulable target gene expression in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[276] C. Glass,et al. The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.
[277] F. Kanai. Transcriptional targeted gene therapy for hepatocellular carcinoma by adenovirus vector , 2001, Molecular biotechnology.
[278] D. Housman,et al. SMAR1, a novel, alternatively spliced gene product, binds the Scaffold/Matrix-associated region at the T cell receptor beta locus. , 2000, Genomics.
[279] R. Müller,et al. Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. , 1998, Human gene therapy.
[280] F. Cosset,et al. T Cell‐specific expression from Mo‐MLV retroviral vectors containing a CD4 mini‐promoter/enhancer , 2000, The journal of gene medicine.